Insert tab A (ACA) into hole B (US health need)
This article was originally published in Scrip
The Affordable Care Act has always been an awkward assembly of pieces, an ill-fitting jigsaw of health modules. The glossy picture on the box shows universal healthcare, a plan for a nation that spends twice as much per capita than any other to ensure that its neediest population decile gets a minimal level of healthcare provision. But the box also contained pieces that didn’t really fit and which had to be hammered into position. The need to construct a legal basis for biosimilars approval was one such.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.